

Interim report

January 1 – March 31, 2022

The first quarter in figures

- Net sales amounted to TSEK 4,260 [2,562].
- The loss after tax amounted to TSEK 9,736 [8,153].
- The loss per share amounted to SEK 0.14 [0.15].
- The cash flow from current operations was negative in the amount of TSEK 10,512 [9,473].
- The gross margin reached 62.8% [52.7%].
- Electrode sales volume increased by 33% and reached 9,982 [7,496] units. Repeat sales of electrodes to existing customers increased by 34%.

Important events during the quarter

- Overall sales increased by 66% [+58%, before currency effects]. The sales in the important US market increased within the area of skin cancer by 541% [in local currency by 475%]. Sales in Germany increased by 54% [49% in local currency].
- SciBase Barrier technology part of major immunodermatology project - Next Generation Immunodermatology. The NGID consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings.

- A new study from the US supporting the use of Nevisense in diagnosing melanoma was published in "SKIN – The journal of cutaneous medicine". The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.
- SciBase further strengthened the patent portfolio as patent application: EP Application No. 18729063.0 was granted by EPO in Europe.
- SciBase announced a change in the Management team and a new head of Quality and Regulatory Affairs

Important events after the end of the period

- A new study performed in Germany and published online in the journal Dermato demonstrated the clinical benefits of Nevisense in day-to-day practice.

Financial overview

THE GROUP	Apr 1 2021 -			
	Jan 1 - Mar 31 2022	Mar 31 2022 2021	Mar 31 2022 Rolling-12	Jan 1 - Dec 31 2021
Net sales, SEK ths	4 260	2 562	13 425	11 727
Gross margin, %	62,8%	52,7%	58,9%	56,1%
Equity/Asset ratio, %	79,3%	79,6%	79,4%	82,8%
Net indebtedness, multiple	0,26	0,26	0,26	0,21
Cash equivalents, SEK ths	54 621	31 403	54 621	65 607
Cashflow from operating activities, SEK ths	-10 512	-9 473	-40 540	-39 501
Earnings per share (before and after dilution), SEK	-0,14	-0,15	-0,66	-0,67
Shareholder's equity per share, SEK	0,88	0,70	0,75	1,13
Average number of shares, 000'	68 475	54 780	66 183	62 739
Number of shares at closing of period, 000'	68 475	54 780	68 475	68 475
Share price at end of period, SEK	4,70	4,78	4,70	5,52
Number of sold electrodes, pieces	9 982	7 496	32 278	29 792
Average number of employees	18	18	18	17

Definitions and a glossary are provided on page 19



Nevisense Go

Nevisense Go is a handheld and fully portable device the size of a large Pen. It combines the company's core Electrical Impedance Spectroscopy (EIS) measurement technology with a new AI-based analysis platform embedded in the device. The result is a flexible platform that will be significantly easier to both collect data and develop applications on. It will also mean products that are easier for clinicians to use and to integrate into a clinic, and better acceptance by patients. The first Nevisense Go version is released for research in skin barrier assessment and is targeted at researchers and Industry partners.

Comment by CEO Simon Grant

"Record 66% sales increase driven by German electrode sales and the US"

Q1 Highlights

- Sales in Q1 increased by 66% [+58% before currency] reaching 4.3MSEK
- Continued traction with US dermatology practice groups, 5 Nevisense systems sold in Q1
- Largest electrode order ever received from single clinic
- SciBase Barrier technology included in an immunodermatology clinical research consortium funded by the EU at 12M€.
- Florida providers have submitted a request for an increased fee schedule to First Coast (Medicare Florida)
- Study from New York University (NYU) published supporting the use of Nevisense.
- SciBase further strengthened its patent portfolio as the patent titled *Method and apparatus for extracting tissue properties from impedance measurement to assist in assessing diseased condition* was granted by the EPO in Europe.
- A German study published demonstrating the benefits of Nevisense in routine clinical use.

Sales growth driven by Germany and the US

Record sales in Germany (+64% vs Q1-21) were the driver for the good sales in the quarter as a number of customers placed large orders before an 8% electrode price rise effective April 1st. This included the single largest order to date for electrodes from a single customer clinic. The order for nearly 2,000 electrodes was from a private German Dermatology clinic and is an illustration of the potential of the Nevisense test. Not all of the large order quantities received in March could be shipped during March, and so we have a good order stock for electrode sales going into Q2. The high order quantities took us a little by surprise but are a very positive indicator that our customers depend on Nevisense in their daily practice.


Apart from the record sales in Germany our US practice group strategy continues to gain traction with an additional 5 Nevisense units (for melanoma) sold in the first quarter to Advanced Dermatology PC (AdvDermPC) in the New York area. Focusing on practice groups continues to prove cost-effective as a way to enter the US market. We also see increasing usage as further systems are installed within the groups. With continued reimbursement progress and positive clinical feedback, we see broad potential for Nevisense in the US.

In total, sales reached MSEK 4.3 for the quarter, an increase before currency effects of 66% making it another record quarter.

Finally, the interest in the barrier application continues and we have mixed progress when it comes to industry partners and researchers. Because of the nature of research purchases, sales in this area will continue to vary by quarter.

Unfortunately, Covid has continued to affect marketing activities negatively with key meetings and

congresses being postponed or shifted to a virtual setting. However, we now believe that the worst is behind us, and we expect to see the establishment of a 'new normal' market from the second quarter of 2022. With our German sales growth, good progress in the US and a high interest in barrier we believe that we will continue our positive sales momentum.



Percentage quarterly sales growth compared to the same quarter in the previous year.

US – progress

Reimbursement coverage is a key requirement for penetrating the US market and we are making progress. Payment is being assigned to all Medicare claims for Nevisense tests in the Florida area which is a very positive development. Our customers continue to work to raise the payment amount.

Our efforts are focused on the regions where our current partners, ADCS (primarily in Florida) and AdvDermPC in the New York area have a high concentration of practices, and we expect to expand our footprint during the remainder of 2022 and forward. We will follow the same procedure in new areas and work with customers to develop demand for the test and submit claims to payers from that region. We continue to expand in our partners networks with 5 systems sold in Q1 to AdvDermPC, and we see a continuous increase in usage and electrodes sold. In the quarter sales of electrodes in the US increased by 67% vs Q1-21.

In March we participated in the AAD (American Association of Dermatology) meeting in Boston, one of the first meetings to be held 'physically' since the start of the pandemic. It was great to be able to meet both current and potential customers face to face.

On the clinical side, a new study supporting the use of Nevisense to improve melanoma diagnosis was published in "SKIN – The journal of cutaneous medicine" in early 2022. The article was authored by, Prof David Polsky from NYU in New York. The article presents further evidence that Nevisense can help clinicians of all experience levels improve their ability to accurately identify lesions that require treatment and



to be more confident in their clinical management decisions.

The remainder of 2022 will involve a significant expansion in both the resources and activity levels for SciBase in the US. We will continue to strengthen our sales team, broaden our geographic focus, and accelerate reimbursement activities.

Operations and gross margin

Our production team has done a fantastic job in streamlining our electrode manufacturing process. This project has focused on increasing our production capacity while reducing the production cost per electrode. We now have sufficient capacity for the medium-term future and are on track to reach our goal of an overall gross margin of 70%. Although the margin will vary between quarters due to product and market mix, we see a continuous positive trend and reached a gross margin of almost 63% in Q1. The 8% increase in electrode sales price in Europe will also start to positively impact gross margins from the end of Q2.

Skin Barrier application – a strategic growth area

Assessment of the skin barrier is a strategic focus for SciBase and an area that we believe has significant future growth potential. Like NMSC, it is based on the same EIS methodology and electrode but using newly developed barrier-specific AI algorithms. Because it is a relatively new method and application, we have targeted the research market and Industry collaborations first. The goal over time is to develop multiple clinical applications that can be used by non-specialists and even eventually by patients in the home.

It was very pleasing to be able to communicate the inclusion of Nevisense and Nevisense Go in the launch of a multidisciplinary research consortium focused on atopic dermatitis and other dermatological disorders. The Next Generation Immunodermatology (NGID) consortium is based in the Netherlands and will run over six years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings. The consortium has received funding of 11.7m euros to stimulate and support innovative approaches to identify and develop novel diagnostic and therapeutic approaches within dermatology. This places Nevisense and EIS right at the center of the development of the next generation of clinical pathways for the management of atopic dermatitis.


The project is a concrete example of how SciBase is helping to advance the management of skin diseases. The importance of the skin barrier in diseases such as atopic dermatitis is well known, but until now it has not been possible to evaluate the barrier in routine clinical practice. SciBase's Nevisense and Nevisense Go were chosen for this project because of their ability to evaluate the skin barrier from an atopic dermatitis perspective in routine clinical and even home use.

The goal of the NGID project is to improve the standard of care within Dermatology and to expand the personalization of disease management to each patient – in other words, to provide the right care to the right patient at the right time. The opportunity for SciBase is to become an integral part of personalized atopic dermatitis management, and with the very high numbers of patients affected, this is one of the most significant opportunities for SciBase to date.

This is but one of many interesting research collaborations we are pursuing and that we hope to be able to communicate on going forward. With Nevisense Go and our AI algorithms, we see the opportunity to revolutionize the way many atopic disorders are monitored and managed. Over time we believe barrier applications will become a significant growth driver for SciBase.

Focus going forward

For SciBase 2022 is about building on the foundation work completed in 2021 to deliver significant sales growth within Europe, the US and the new applications. We have started the year well and expect to see continued growth as the year progresses. While the base business within melanoma is developing well, the new applications are especially exciting, and I look forward to sharing more news in the coming months.



Simon Grant, CEO
Sundbyberg May 12th, 2022



SciBase in brief

About SciBase

SciBase, a medical technology company, is a leading developer of augmented intelligence-based solutions for skin disorders. SciBase develops instruments for the detection of skin cancer and other skin conditions such as atopic dermatitis. Nevisense can detect melanoma, the most dangerous form of skin cancer, directly on the skin without needing to cut away suspected moles. The product is based on comprehensive research within Electrical Impedance Spectroscopy (EIS), and SciBase has conducted the largest study to date on the detection of melanoma, in which Nevisense achieved excellent results. The study was published in the prestigious British Journal of Dermatology. Nevisense is approved for sale in the United States (PMA), Europe (CE mark, under MDR) and Australia (TGA).

Besides melanoma, SciBase is developing further research and clinical applications for Nevisense. Using Nevisense as a platform, the Company has added applications based on the same EIS method to assess non-melanoma skin cancer, skin barrier and atopic dermatitis. SciBase sold the first Nevisense systems for the evaluation of the skin barrier function to leading researchers in 2019.

SciBase has also miniaturized the Nevisense hardware platform through the development of an Application Specific Integrated Circuit (ASIC). The new product platform, Nevisense Go, was released at the end of 2020 for research use.

SciBase was founded in 1998 by Associate Professor Stig Ollmar, a researcher at The Karolinska Institute. The Company is headquartered in Sundbyberg, Stockholm and is listed on the Nasdaq First North Growth Market.

Business model

The company's business model is based on customers initially purchasing a Nevisense or Nevisense Go device then buying consumables (electrodes) on an on-going basis. Each electrode can only be used on one patient but can test up to 20 moles or skin areas.

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- In the United States, expenditure for the treatment of melanoma reached USD 3.3 billion in 2011, equivalent to 41% of expenditure for skin cancer. In the preceding 5 year period, melanoma management cost increased four-fold.
- Today, some 50-60 million annual examinations for melanoma are performed, of which 5-6 million lead to excisions. Of these, some 86-97% are shown to be benign.
- With SciBase's Nevisense® the number of unnecessary interventions can be reduced by up to 50%, representing a reduction of over two million interventions annually and thus leading to significant cost savings.
- The number of patients affected by non-melanoma skin cancer (NMSC) is over ten times the number affected by melanoma. In the US there are approximately 2.8M cases of basal cell carcinoma (a common type of NMSC) each year
- Nevisense® provides physicians with an objective instrument to support better diagnoses.
- Management of atopic dermatitis (eczema) represents the greatest burden globally of all skin diseases. As many as 20 percent of all children and between 1 and 10 percent of all adults are afflicted by atopic dermatitis.

Certified Advisor (CA)

Vator Securities





Email: ca@vatorsec.se

Tel: +46 8 580 065 099

"We are excited to integrate Nevisense into our skin cancer exams to offer the most advanced technology for the earliest possible detection of melanoma at the point of care", says Dr. Matt Leavitt, Chairman and Founder of Advanced Dermatology and Cosmetic Surgery

US facts

- In 2022 there are expected to be around 97,980 invasive melanoma cases and in 2021 around 7,180 deaths estimated from melanoma in the US
- There are more cases of skin cancer than all other cancers combined – though only 3% of these cases are melanoma
- Melanoma is the fifth most common cancer among both men and women
- The lifetime risk for melanoma in the US is 1 in 24



First quarter

Net Sales

Net sales for the first quarter of 2022 amounted to TSEK 4,260 (2,562), an increase of 66%. Cleared for currency effects the sales increased by 58%. The increased sales are mainly due to record sales of electrodes in Germany. A number of customers placed large orders before an 8% electrode price rise from April 1st. This included the single largest order to date for electrodes from a single customer clinic. Not all of the large order quantities received in March could be shipped in the period, which means a good order stock for electrode sales going into Q2. Apart from Germany the US also contributed to the good sales increase with the continued sales of Nevisense systems (5) to one of the Company's partners, AdvDermPC in the New York region, as well as continued good electrode sales. Sales of devices amounted to TSEK 696 (263) and sales of electrodes to TSEK 3,565 (2,300). The sales within the new skin barrier application were TSEK 101 (255) in the period. These sales are for research purposes and to potential industrial partners. Given the nature of research sales it will vary between the quarters.

Sales are still to some extent affected by Covid-19, primarily through the delay or cancelled meetings. As an example, one of the Company's key meetings in Germany has been moved from March to July.

Sales in Germany in the skin cancer area accounted for 77 (88%) of the sales in the period and increased by 54% compared to Q1 2021. In local currency the sales in Germany increased by 49%. The sales and order inflow in the quarter were relatively high following an announced price increase of 8% from April 1st on the electrode.

The sales in the US in the skin cancer area accounted for 21 (5)% of the sales in the period. The Company's US

practice group strategy continues to gain traction with an additional 5 Nevisense units (for melanoma) sold in the first quarter to AdvDermPC in the New York area.

The total sales of electrodes in the quarter reached 9,982 (7,496), an increase of 33%. In Germany, the total sales of electrodes within skin cancer in volume increased by 47% and in the US by 67%. Total repeat sales of electrodes increased by 34%.

Operating profit/loss

The operating loss for the period January - March 2022 amounted to TSEK 9,697 (8,111), an increased loss of TSEK 1,586. Although the increased sales and an improved gross margin improved earnings, increased investments in the US and a return to a more normal market activity level in general meant that the overall operating loss increased compared with Q1 2021. The operating income was negatively affected by currency effects with around MSEK 0.1.

The gross margin in the period was 62.8 (52.7%). When cleared for currency effects the gross margin would have been closer to 61%. The improved margin is both the result of improvements in the production process as well as increased US sales. The overall margin remains very dependent on electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 1,025 and amounted to TSEK 7,040 (6,014). The expense increase was primarily due to increased US resources and marketing activities as well as a general return to a more normal marketing activity level.

Administration expenses for the period amounted to TSEK 2,582 (2,288), an increase of TSEK 293. The in-

crease was mainly due to increased travel and quality activities related to MDR. Development expenses for the period amounted to TSEK 3,090 (1,662), an increase of TSEK 1,427. Costs increased as a result of projects related to production process improvements, clinical trials and product development projects.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents amounted to TSEK 65,607 and, at the end of the period, to TSEK 54,621.

Cash flow from current operations for the period was negative to the amount of TSEK 10,512 (9,473), of which

changes in working capital amounted to a negative TSEK 850 (negative 1,604) which was mainly attributable to a decreased inventory and increased receivables. The negative operating cash flow deteriorated mainly due to the increased loss. Total cash flow for the period was negative to the amount of TSEK 11,120 (negative 10,009).

Net investments in tangible assets for the period amounted to TSEK 0 (0). Investments in intangible assets for the period amounted to TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 1,005 (662) of which TSEK 724 (536) are due to leased assets.

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 3,894 shareholders, of whom the five largest represented approximately 32.4% of the capital and votes. The total number of shares per March 31, 2022 amounts to 68,475,107. The largest shareholders as per March 31, 2022 were Avanza pension (11%), Futur Pension (6%), SIX SIS AG (6%) Nordnet pensionsförsäkring (5%) and Fouriertransform AB (4%).

Market overview

Skin cancer

SciBase is active within both skin cancer detection and skin barrier assessment.

Skin cancer is believed to be the most common form of cancer in the world. More than 3.5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. Currently around 50 million formal skin cancer screenings are estimated to be performed annually in SciBase's target geographies. The cost for these 50 million screenings is estimated to be around USD 2 billion. SciBase estimates that at least 10-15 percent of patients or more than 7 million lesions are suspicious enough to be excised and examined for melanoma. SciBase estimates that in addition to the 7 million lesions currently excised or biopsied in the company's addressable geographies, there are an additional 1–2 million lesions that are not suspicious enough to excise or biopsy but are still of some concern. Together with the 7 million lesions currently excised SciBase estimate the total addressable market potential for SciBase to be around 400 million USD per year or approximately BSEK 3.7.

Of the seven million estimated annual excisions performed in SciBase's target markets around 86-97% are later found to be benign. Uncertainty in the detection of melanoma due to inexperience and limitations of visual screening methods leads physicians to excise many lesions 'just in case', as physicians do not want to risk missing a melanoma. Despite this over-excision as many as 13% of all melanomas are missed. The excision and biopsy of benign (harmless, i.e. not skin cancers) lesions due to uncertainty of visual screening methods

is estimated to cost payers around USD 1.5 billion annually. SciBase estimates that Nevisense could reduce the number of benign lesion excisions by 34-50%.

The population of non-melanoma skin cancer patients includes more than ten times the number of patients compared to the melanoma patient population though the need for testing is not so acute. SciBase estimates that the potential for the use of Nevisense amounts to at least 4 million examinations or tests annually. Given this, non-melanoma skin cancer is estimated to have a total market potential of approximately SEK 1.4 billion annually. Although non-melanoma skin cancer is less harmful than melanoma, SciBase sees the addition of the indication as important for users and necessary to increase market penetration, especially in Germany. Dermatologists see many times more patients with suspected non-melanoma skin cancer than with suspected melanoma, which means that the potential for performing tests with Nevisense is significantly increased.

Skin barrier

An exciting new application area is skin barrier assessment. The skin barrier stops irritants and allergens entering and water from leaving the body. An impaired skin barrier at birth can for instance be a predictor of the development of Atopic Dermatitis (AD) or eczema. The development of AD often precedes the development of other atopic diseases such as food allergies, allergic rhinitis and asthma. The ability to easily detect an impaired skin barrier can help detect, manage and treat atopic diseases before the development of AD. There is a high interest from the research community and this group will be the short-term sales target within the barrier area.

In the application area of the skin's barrier assessment, prediction of disease onset and improving the management of atopic dermatitis are considered to be the largest potential markets. The application area includes disease development prediction in infants, diagnostic and therapy selection tests in a clinical setting, and regular tests in the home in order to monitor and manage the disease. Furthermore, there are many areas within research where the ability to evaluate the skin

barrier in a clinical environment or at home has significant value and potential. Given this, the total number of measurements for all patients with atopic dermatitis could potentially exceed the tens of million per year. In the market estimates for skin barrier assessments, the Company expects lower electrode prices. Even so, and only based on two sub-groups (patients with chronic severe recurring eczema episodes and prediction of AD in infants) the total addressable market for the application area skin barrier function is estimated at approximately SEK 3 billion annually.

Employees

At the end of the period, the number of employees amounted to 18 [18], of whom 28 [22]% were women. This includes the production employees at our Uppsala electrode production facility and salespeople in Germany and the US.

Financing

The Board of Directors regularly reviews the company's existing and forecast cash flows to ensure that the company has the funds and resources necessary to pursue operations and strategic focus adopted by the Board. The company's long-term cash requirements are determined by how successful the Company will be able to commercialize its product Nevisense. Commercialization is, in turn, dependent on a variety of factors that will affect the need, including costs related to being included in insurance systems, granted compensation levels therein, marketing costs and obtaining and enforcing regulatory requirements.

As of March 31, 2022, the Group's cash and cash equivalents amounted to SEK 54.6 million. Based on the positive signals from the US market, the promising new application areas and the sales trend in Germany (excluding Covid-19 effects) the Board believes that the Company is on the right track. Based on this, it is the Board's opinion that the company has sufficient working capital for at least the coming 12-month period based on the current strategic plan.

Transactions with related parties

During the period, the parent Company SciBase Holding AB has invoiced TSEK 1,186 [1,077] to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the year. In addition, the company has a separate consulting agreement in place with the board member Matt Leavitt (appointed in 2021) The agreement was entered into prior to him being appointed as a board member and relates to consultancy support for the regional reimbursement processes and US market introduction as well as Nevisense rollout guidance following positive reimbursement decisions. The agreement has a one-year duration with the option to extend. In the period he was remunerated KUSD 75 [10] for services under this agreement. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency

and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward-looking information. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 30-34 of SciBase's 2021 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per March 31, 2022, there were three employees, the CEO and the Groups finance department. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 1,186 [1,077]. The loss for the period amounted to TSEK 7,047 [6,373]. The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB from 2016 and is charged to earnings and not booked as a financial tangible asset. The shareholders contribution expensed during the period was MSEK 5,6 [5,2].

Significant events during the quarter

SciBase Barrier technology part of major immunodermatology project - Next Generation Immunodermatology. The NGID consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings.

A new US based study supporting the use of Nevisense in diagnosing melanoma has been published in "SKIN – The journal of cutaneous medicine". The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perleman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.

SciBase has appointed Alf Laurell as Director of Quality Assurance and Regulatory Affairs and Person for Regulatory Compliance (PRRC) for SciBase. Alf joins SciBase from Elekta in Stockholm. The previous head of Quality and Regulatory and PRRC, Niklas Jakobsson has decided to pursue a new opportunity outside the company and as such leaves the SciBase Management team.

Significant events after the period

A new study from Germany demonstrated the clinical benefits of Nevisense in day-to-day practice. The study titled – **“Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies”** and authored by Dr Liebich et al was published online in the journal *Dermato*. The study looked at the real-life clinical effectiveness of Electrical Impedance Spectroscopy (EIS) when using Nevisense to detect malignancies in an everyday clinical setting. In summary, the study clinic showed a reduction in the number of unnecessary excisions of 47%, while still detecting 100% of melanomas. Clinicians combine Nevisense with visual and dermatoscopic examinations to identify atypia in the cell structure of lesions that normally cannot be seen. The result provides better identification of

which lesions to biopsy or excise and which lesions to leave.

The annual report for 2021 was published on April 22nd, 2022..



Consolidated summary Income Statement

SEK 000'	Jan 1 - Mar 31		Apr 1, 2021 -	
	2022	2021	Mar 31, 2022 Rolling-12	Jan 1 - Dec 31 2021
Net sales	4 260	2 562	13 425	11 727
Cost of goods sold	-1 586	-1 213	-5 521	-5 148
Gross Profit/Loss	2 674	1 349	7 904	6 579
Sales and marketing expenses	-7 040	-6 014	-28 291	-27 266
Administration expenses	-2 582	-2 288	-10 098	-9 805
Development expenses	-3 090	-1 662	-13 191	-11 764
Other operating income	0	0	91	91
Other operating expenses	339	504	395	560
Operating Income	-9 697	-8 111	-43 192	-41 605
Financial income	0	0	1	1
Financial expenses	-39	-42	-171	-173
Profit/Loss before taxes	-9 736	-8 153	-43 361	-41 778
Income tax	0	0	0	0
Profit/Loss for the period	-9 736	-8 153	-43 361	-41 778
Net Profit/Loss attributable to:				
Parent company shareholders	-9 736	-8 153	-43 361	-41 778
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)				
Profit/loss per share (before and after dilution)*	-0,14	-0,15	-0,66	-0,67
Average number of shares outstanding	68 475	54 780	66 183	62 739

Consolidated summary statement of comprehensive income

SEK 000'	Jan 1 - Mar 31		Apr 1, 2021 -	
	2022	2021	Mar 31, 2022 Rolling-12	Jan 1 - Dec 31 2021
Profit/loss for the period	-9 736	-8 153	-43 361	-41 778
<i>Other comprehensive income for the period:</i>				
<i>Items that have or may be reclassified to profit or loss:</i>				
Changes in fair value on financial assets that can be sold	0	0	0	0
Tax effect attributable to changes in fair value on financial assets that can be sold	0	0	0	0
Translation differences on foreign operations	-823	-290	-1 305	-773
Sum other comprehensive income	-823	-290	-1 305	-773
Total comprehensive income for the period	-10 559	-8 443	-44 667	-42 551
Total comprehensive income attributable to:				
Parent company shareholders	-10 559	-8 443	-44 667	-42 551



Consolidated summary statement of financial position

SEK 000'	Mar 31		Dec 31
	2022	2021	2021
ASSETS			
<i>Fixed Assets</i>			
Tangible fixed assets	6 221	4 640	5 117
Financial fixed assets	0	0	0
Total Tangible Assets	6 221	4 640	5 117
<i>Current Assets</i>			
Inventory	6 674	7 246	6 800
Current tax receivable	706	697	548
Receivables	4 569	2 388	3 469
Other current receivables	3 218	1 892	3 916
Cash equivalents	54 621	31 403	65 607
Total Current Assets	69 787	43 627	80 340
Total Assets	76 008	48 267	85 456
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	60 237	38 417	70 796
<i>Longterm Liabilities</i>			
Deferred tax liability	0	0	0
Other longterm liabilities	1 883	0	356
Total Longterm Liabilities	1 883	0	356
<i>Current Liabilities</i>			
Accounts payable	2 571	775	2 740
Other current liabilities	11 317	9 075	11 565
Total Current Liabilities	13 888	9 850	14 305
Total Liabilities	15 771	9 850	14 661
Total shareholders' equity and liabilities	76 008	48 267	85 456



Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Reserves	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2021	2 739	571 755	-269	-527 365	46 861
Profit/loss for the period				-8 153	-8 153
Other comprehensive income			-290		-290
Total comprehensive income	0	0	-290	-8 153	-8 443
Total transactions with shareholders	0	0	0	0	0
Closing balance Mar 31, 2021	2 739	571 755	-559	-535 518	38 417
Opening balance Jan 1, 2022	3 424	637 727	-120	-570 235	70 796
Profit/loss for the period				-9 736	-9 736
Other comprehensive income		-244	-423	-156	-823
Total comprehensive income	0	-244	-423	-9 892	-10 559
Total transactions with shareholders	0	0	0	0	0
Closing balance Mar 31, 2022	3 424	637 483	-543	-580 127	60 237

Consolidated summary statement of cash flows

SEK 000'	Jan 1 – Mar 31		Apr 1, 2021 –	Jan 1 – Dec 31
	2022	2021	Mar 31, 2022 Rolling-12	2021
Cashflow from operating activities before change in working capital	-9 662	-7 869	-41 636	-39 843
<i>Cashflows from changes in working capital</i>				
Change in Inventory	126	-334	573	112
Change in Receivables	-560	-452	-3 515	-3 407
Change in Liabilities	-417	-818	4 038	3 637
<i>Total change in working capital</i>	-850	-1 604	1 096	342
Cashflow from operating activities	-10 512	-9 473	-40 540	-39 501
<i>Investment activities</i>				
Acquisitions of Fixed Assets	0	0	-617	-617
Divestment of fixed assets	0	0	91	91
Divestment of financial assets	0	0	0	0
Cashflow from investment activities	0	0	-526	-526
<i>Financing activities</i>				
New share issues	0	0	71 214	71 214
Expenses related to new share issues	0	0	-4 728	-4 728
Amortization leasing contracts	-608	-536	-2 341	-2 269
Cashflow from financing activities	-608	-536	64 146	64 217
Cashflow for the period	-11 120	-10 009	23 080	24 191
Cash equivalents at start of the year	65 607	41 427	31 403	41 427
Exchange rate differences in cash equivalents	134	-15	138	-11
Cash equivalents at end of the period	54 621	31 403	54 621	65 607



Income statement, Parent Company

SEK 000'	Jan 1 - Mar 31		Apr 1 2021 -	
	2021	2020	Mar 31, 2022	Jan 1 - Dec 31
			Rolling-12	2021
Net Sales	1 186	1 077	4 416	4 306
Gross profit	1 186	1 077	4 416	4 306
Administration expenses	-2 589	-2 282	-10 774	-10 466
Other expenses	0	-	0	0
Operating Profit/loss	-1 403	-1 205	-6 358	-6 160
<i>Earnings from financial items:</i>				
Profit/Loss from shares in group companies	-5 644	-5 167	-32 970	-32 493
Financial income	0	0	0	0
Financial expenses	0	0	0	0
Profit/loss after financial items	-7 047	-6 373	-39 328	-38 653
Taxes	-	-	-	-
Profit/loss for the period	-7 047	-6 373	-39 328	-38 653

Statement of other comprehensive income, Parent Company

SEK 000'	Jan 1 - Mar 31		Apr 1 2021 -	
	2021	2020	Mar 31, 2022	Jan 1 - Dec 31
			Rolling-12	2020
Profit/loss for the period	-7 047	-6 373	-39 328	-38 653
<i>Other comprehensive income</i>	-	-	-	-
Total other comprehensive income	-	-	-	-
Total comprehensive income	-7 047	-6 373	-39 328	-38 653



Summary Balance Sheet, Parent Company

SEK 000'	Mar 31		Dec 31
	2022	2021	2021
ASSETS			
<i>Fixed Assets</i>			
Shares in Group Companies	137 647	137 647	137 647
Total Fixed Assets	137 647	137 647	137 647
<i>Current Assets</i>			
Current receivables and prepaids	47 883	21 252	51 986
Cash equivalents	16 018	14 995	19 424
Total Current Assets	63 902	36 247	71 410
TOTAL ASSETS	201 548	173 893	209 057
SHAREHOLDERS' EQUITY AND LIABILITIES			
<i>Shareholder's equity</i>			
Restricted equity			
Share capital	3 424	2 739	3 424
Non-restricted equity			
Other capital contributions	637 610	571 808	637 610
Retained earnings	-435 380	-396 727	-396 727
Profit/Loss for the period	-7 047	-6 373	-38 653
Shareholders equity	198 606	171 448	205 653
<i>Current Liabilities</i>			
Current liabilities	2 942	2 446	3 403
Total liabilities	2 942	2 446	3 403
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	201 549	173 893	209 057



Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report with the exception of what is stated below. Significant accounting and valuation principles are detailed on pages 43-48 of the consolidated annual report for 2021.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Financial fixed assets

The Groups financial fixed assets, which consisted of cash funds, were divested during Q2 2020.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB to secure that the equity at minimum corresponds to the share capital that is valid until the end of 2022. A corresponding agreement was in-place in 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today two operating segments, skin cancer and skin barrier assessment. Follow-ups are in addition done on the geographical areas, Europe/Rest of the World, US/North America and Asia/Oceania.

First quarter

Skin cancer

Europe/Rest of the World

Net sales during the period amounted to TSEK 3,286 [2,171] of which Germany accounted for 100 [98]%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. Gross profit amounted to a profit of TSEK 1,965 [1,167].

Other geographical areas

Net sales during the period amounted to TSEK 874 [136]. Gross profit amounted to TSEK 638 [68]. The sales consisted mainly of the sale of 5 Nevisense systems to a larger dermatology groups as well as additional sales of electrodes.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe/Rest of the World

Net sales during the period amounted to TSEK 0 [82]. Gross profit amounted to a profit of TSEK 0 [37]. The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 101 [173]. Gross profit amounted to TSEK 72 [76]. The sales were to researchers and industry within the skin barrier field.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Note 6 Incentive program

The Board considers it as important and positive if the employees' ownership in the company increases. The Board has evaluated different incentive programs and following this decided to implement a normal bonus program. However, the purpose is to increase the employees' ownership in the company. Thus, if the employee undertakes to buy shares over the market and enter into a lockup agreement [12-months], the bonus is increased by 4 times the cash bonus. The program has a maximum ceiling (including social security fees etc) of SEK 3 million, For the full year 2021 the total cost was SEK 1.7 million.

Operating segments

SEK 000'	Jan 1 - Mar 31, 2022			Jan 1 - Mar 31, 2021		
	Europe/ Rest of the World	Other Segments	Total	Europe/ Rest of the World	Other Segments	Total
Skincancer - Net sales	3 286	874	4 160	2 171	136	2 307
The skin barrier function - Net Sales	0	101	101	82	173	255
Sales between segments	-	-	-	-	-	-
Net sales from external customers	3 286	975	4 260	2 253	309	2 562
Cost of goods - Skincancer	-1 321	-237	-1 558	-1 003	-68	-1 072
Cost of goods - Barrier function	0	-29	-29	-45	-96	-141
Cost of goods - total	-1 321	-265	-1 586	-1 048	-165	-1 213
Gross Profit - Skincancer	1 965	638	2 602	1 167	68	1 236
Gross Profit - Barrier function	0	72	72	37	76	114
Gross Profit - total	1 965	709	2 674	1 205	144	1 349
Operating expenses			-12 372			-9 461
Operating profit/Loss			-9 697			-8 111
Financial Income			0			0
Financial Expenses			-39			-42
Group earnings - before tax			-9 736			-8 153

Net sales per category and segment

Amounts in KSEK	Jan 1 - Mar 31 2022		Jan 1 - Mar 31 2021		Rolling-12		Full Year 2021	
	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments	Europe/ Rest of the World	Other segments
<i>Skin cancer</i>								
Electrodes	3 038	524	2 008	136	8 961	1 328	7 930	941
Instruments	247	350	164	0	941	1 316	857	965
Total Skin Cancer	3 286	874	2 171	136	9 902	2 644	8 787	1906
<i>Skin barrier function</i>								
Electrodes	0	3	32	123	159	199	192	320
Instruments	0	98	50	49	66	454	116	406
Total skin barrier function	0	101	82	173	226	654	308	726
<i>Total</i>								
Electrodes	3 038	526	2 040	260	9 120	1 528	8 122	1 261
Instruments	247	449	213	49	1 008	1 770	973	1 371
Total	3 286	975	2 253	309	10 128	3 298	9 095	2632



Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

[SciBase Holding AB]
Stockholm, May 12, 2022

Tord Lendau
Chairman of the Board

Diana Ferro
Board member

Thomas Taapken
Board member

Matt Leavitt
Board member

Jvalini Dwarkasing
Board member

Simon Grant
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 12, 2022.

This year-end report has not been subject to review by the Company's auditors

Contact person:
Michael Colérus, CFO, +46 70 341 34 72

Quarterly overview

THE GROUP	2022		2021			2020			
	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net sales, SEK ths	4 260	3 925	2 982	2 258	2 562	3 055	2 287	1 683	2 496
Gross margin, %	62,8%	52,8%	63,3%	56,3%	52,7%	49,4%	52,7%	55,7%	54,0%
Equity/Asset ratio, %	79,3%	82,8%	86,8%	87,3%	79,6%	79,1%	67,0%	69,2%	64,8%
Net indebtness, multiple	0,26	0,21	0,15	0,15	0,26	0,26	0,49	0,44	0,54
Cash equivalents, SEK ths	54 621	65 607	78 270	88 192	31 403	41 427	21 724	30 450	17 970
Cashflow from operating activities, SEK ths	-10 512	-11 709	-9 156	-9 162	-9 473	-10 290	-6 974	-8 704	-7 893
Earnings per share (before and after dilution), SEK	-0,14	-0,20	-0,13	-0,19	-0,15	-0,20	-0,20	-0,38	-0,38
Shareholder's equity per share, SEK	0,88	1,03	1,24	1,59	0,70	0,96	0,71	1,44	1,40
Average number of shares, 000'	68 475	68 475	68 475	59 265	54 780	48 707	36 560	23 265	16 618
Number of shares at closing of period, 000'	68 475	68 475	68 475	68 236	54 780	54 780	36 560	36 560	16 618
Share price at end of period, SEK	4,70	5,52	4,88	5,52	4,78	4,62	4,00	2,44	1,84
Number of sold electrodes, pieces	9 982	8 024	8 304	5 968	7 496	7 492	6 924	4 672	6 598
Average number of employees	18	18	17	17	18	17	16	16	16

Definitions

Financial key ratios

- **TSEK:** SEK 000'
- **Gross margin, %:** Gross profit divided by net sales.
- **Operating profit:** Operating income less operating expenses.
- **Operating margin, %:** Operating profit divided by income.
- **Equity/assets ratio:** Equity at the end of the period divided by total assets at the end of the period.
- **Debt/equity ratio:** Total liabilities in relation to equity.
- **Earnings per share for the period before dilution:** Profit for the period divided by average number of shares before dilution.
- **Earnings per share for the period after dilution:** Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Shareholders' equity per share:** Equity divided by average number of shares.
- **Dividend per Share:** Dividend for the period divided by average number of shares after dilution.
- **Number of shares before dilution at the end of the period:** Number of shares in issue before dilution at the end of the period.
- **Average number of shares before dilution:** Average number of shares during the period before dilution.
- **Average number of shares after dilution:** Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Number of employees (average):** Weighted average number of employees in the relevant period.
- **IFRS:** International Financial Reporting Standards

Industry specific glossary

- **CE labeling:** A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA, or intended for sale there.
- **Dermatoscopy or Dermoscopy:** Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- **Electrical Impedance Spectroscopy (EIS):** A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- **FDA:** The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- **Melanoma:** The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- **Unnecessary excision:** The removal of benign skin lesions/birthmarks.
- **Nevi:** Lesions.
- **PMA:** Pre-Market Approval, a form of approval from the US FDA required for all new Class III devices.

Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

APM for the period:

Gross Margin (%)

	2022	2021
Gross Profit	2 674	1 349
Net Sales	4 260	2 562
Gross Margin (%)	62,8%	52,7%

Definition:

Gross Profit / Loss divided with Net Sales.

Cause of use:

The gross margin shows the difference between net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as product mix, price trends, exchange rate fluctuation, efficiency in manufacturing processes etc. This is an important measurement as it provides a better understanding of the Company's progress.

Shareholder Equity ratio (%)

	2022	2021
Total Shareholders' Equity	60 237	38 417
Total Assets	76 008	48 267
Shareholders' Equity ratio (%)	79,3%	79,6%

Definition:

Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.

Cause of use:

Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.

Debt ratio (times)

	2022	2021
Total Liabilities	15 771	9 850
Total Shareholders' Equity	60 237	38 417
Debt ratio (times)	0,26	0,26

Definition:

Total debt in relation to Total Shareholders' Equity.

Cause of use:

The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of shareholders' equity. It is closely connected to the Shareholder's equity ratio.

Earnings per share, after dilution (sek)

	2022	2021
Profit/Loss for the period	-9 736	-8 153
Average number of shares (thousand)	68 475	54 780
Earnings per share (sek)	-0,14	-0,15

Definition:

Is the portion of a company's profit allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.

Cause of use:

This shows the value per share.

Shareholders' equity per share (sek)

	2022	2021
Shareholders' Equity	60 237	38 417
Average number of shares (thousand)	68 475	54 780
Shareholders' equity per share	0,88	0,70

Definition:

Shareholders' equity divided with the average number of shares after dilution

Cause of use:

The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price

Average number of shares (thousand)

	2022	2021
Opening balance - Jan 1	68 475	54 780
Closing balance - Dec 30	68 475	54 780
Average number of shares (thousand)	68 475	54 780

Definition:

The average number of issued shares.

Cause of use:

The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.



Simon Grant
CEO
+46 72 887 43 99
simon.grant@scibase.com

Read more about the company and its operations at our website >> www.scibase.com



Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Future reporting dates

- ACM May 18, 2022
- Interim report Q2, August 18 2022
- Interim report Q3, November 10 2022
- Year-end report, February 2023